Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research data from M. Campone and colleagues update understanding of breast cancer
April 16th, 2009
According to recent research published in the journal Cancer Chemotherapy and Pharmacology, "Combination of intravenous (i.v.) vinorelbine and docetaxel was shown to be feasible and effective in metastatic breast cancer (MBC). In an effort to improve patient convenience, we investigated in first-line treatment a regimen alternating i.v. and oral vinorelbine in combination with docetaxel." "Forty-nine patients (median age, 53 years) with MBC received a maximum of 6 cycles consisting of i.v. vinorelbine 20 mg/mA(2) plus docetaxel 60 mg/mA(2) given on day 1, and oral vinorelbine 60 mg/mA(2) on day 15 every 3 weeks in an open-label, multicentre phase II study...
Source: Women's Health Weekly (2009-04-16)
|
